How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,649 results for

Thyroid Function Summary

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Evaluation of 18F-FDOPA PET-CT in the Preoperative Initial Assessment of Medullary Thyroid Carcinoma

Recruitment Status : Not yet recruiting First Posted : August 17, 2018 Last Update Posted : August 17, 2018 See Sponsor: Assistance Publique Hopitaux De Marseille Information provided by (Responsible Party): Assistance Publique Hopitaux De Marseille Study Details Study Description Go to Brief Summary: Medullary thyroid carcinoma (MTC) develops at the expense of calcitonin cells and is often characterized by lymph node metastases and sometimes visceral metastases. Improvement of preoperative diagnosis (...) Evaluation of 18F-FDOPA PET-CT in the Preoperative Initial Assessment of Medullary Thyroid Carcinoma Evaluation of 18F-FDOPA PET-CT in the Preoperative Initial Assessment of Medullary Thyroid Carcinoma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please

2018 Clinical Trials

82. Long Non Coding RNA HOTAIR and Midkine as Biomarkers in Thyroid Cancer

See Sponsor: Assiut University Information provided by (Responsible Party): Hala Saleh Abdelghafour, Assiut University Study Details Study Description Go to Brief Summary: Thyroid cancer is the most prevalent endocrine malignancy.Papillary thyroid carcinomas and follicular thyroid carcinomas account for 95% of all thyroid cancer cases. They are clinically classified as well-differentiated thyroid carcinomas due to their biological behavior resembling normal follicular cells and good responsiveness (...) or disease Intervention/treatment Thyroid Cancer Other: complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body specific test Real time polymerase chain reaction Detailed Description: Thyroid cancer is the most prevalent endocrine malignancy.Papillary thyroid carcinomas and follicular thyroid carcinomas account for 95% of all thyroid cancer cases. They are clinically classified as well-differentiated thyroid

2018 Clinical Trials

83. Study on Application of Suturing Parathyroid Markers in Thyroid Cancer Surgery

, 2018 See Sponsor: Bo Wang,MD Information provided by (Responsible Party): Bo Wang,MD, Fujian Medical University Study Details Study Description Go to Brief Summary: To study the protective effect of suture parathyroid marker method on the function of parathyroid gland in thyroid cancer surgery Condition or disease Intervention/treatment Phase Thyroid Cancer Hypoparathyroidism Marker; Structural Complication of Surgical Procedure Parathyroid Function Low Adverse Event Procedure: The suture marks (...) Study on Application of Suturing Parathyroid Markers in Thyroid Cancer Surgery Study on Application of Suturing Parathyroid Markers in Thyroid Cancer Surgery - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2018 Clinical Trials

84. A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.

First Posted : March 19, 2018 Last Update Posted : January 10, 2019 See Sponsor: AHS Cancer Control Alberta Collaborator: Alberta Cancer Foundation Information provided by (Responsible Party): AHS Cancer Control Alberta Study Details Study Description Go to Brief Summary: Thyroid cancers that have spread beyond the neck are not curable. About 30,000 people worldwide die from thyroid cancer every year. Usually, thyroid cancers get worse because the cancer cells become more and more abnormal through (...) and thyroid cancer dedifferentiation. PDGFRα helps cancer progression and lowers the ability of sodium iodine symporters to move radioiodine into cells where it would normal act to kill the cancer cells. PDGFRα therefore makes thyroid cells resistant to radioactive iodine. Imatinib is an anti-cancer drug that blocks PDGFRα function. It has been used for many years to treat other cancers such as leukemia. The investigators who wrote this study believe that, base on laboratory testing, if thyroid cancer

2018 Clinical Trials

85. Study of the Feasibility of Radiofrequency Ablation of Benign Thyroid Nodules

Update Posted : December 3, 2018 See Sponsor: University Hospital, Toulouse Information provided by (Responsible Party): University Hospital, Toulouse Study Details Study Description Go to Brief Summary: The purpose of the present protocol is to evaluate the response rate to treatment of these symptomatic benign nodules with radiofrequency as an alternative to surgical treatment. This thyroid nodules ablation with radiofrequency will be directed by a single percutaneous procedure guided by ultrasound (...) . The procedure includes an ultrasound with percutaneously radiofrequency ablation of benign thyroid nodule. Clinical and ultrasonographic monitoring will last a year with consultations at 2 weeks (consultation only), 3 months, 6 months and 1 year (consultation, ultrasound TSH). The success of this procedure will be controlled with 3 successive ultrasounds the following year. The expected results are a decrease in the size of the nodule by at least 50% and a reduction in the functional and aesthetic

2018 Clinical Trials

86. Efficacy of a Spirulina Supplement for Amelioration of Benign ThYroid Nodules

: June 5, 2018 See Sponsor: Fundatia Bio-Forum Information provided by (Responsible Party): Fundatia Bio-Forum Study Details Study Description Go to Brief Summary: Clinical trial with a double-blind, placebo-controlled, crossover design; enrolls approximately 30 euthyroid patients with benign thyroid nodules, who will receive for 6 weeks a spirulina-based supplement, and for another 6 weeks placebo. Thyroid ecography will be performed three times for each patient, and blood tests including TSH, free (...) levels of the molecules which reflect thyroid function Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 30 participants Allocation: Non-Randomized Intervention Model: Crossover Assignment Masking: Double (Participant, Care Provider) Primary Purpose: Treatment Official Title: Evaluation of the Efficacy of a Supplement With Spirulina for Amelioration of Benign Thyroid Nodules Actual Study Start Date : May 15, 2018 Estimated

2018 Clinical Trials

87. Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil

: December 17, 2018 Sponsor: Eisai Inc. Information provided by (Responsible Party): Eisai Inc. Study Details Study Description Go to Brief Summary: This is an Expanded Access Program to make lenvatinib available to participants with radioiodine-refractory differentiated thyroid cancer in Brazil. Participants who have no other treatment options available, and who, in the opinion and clinical judgment of the treating physician, would benefit from treatment with lenvatinib will be enrolled (...) Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please

2018 Clinical Trials

88. Alterations in Quality of Life After Thyroidectomy for Benign Thyroid Disease

, 2018 See Sponsor: Aristotle University Of Thessaloniki Information provided by (Responsible Party): Papavramidis Theodossis, Aristotle University Of Thessaloniki Study Details Study Description Go to Brief Summary: To detect any changes in Quality of Life in patients with benign thyroid diseases who undergo thyroidectomy compared to patients with benign thyroid diseases and conservative treatment and healthy subjects. Condition or disease Intervention/treatment Benign Thyroid Nodule Quality of Life (...) Frame: 2 years ] Correlation of alterations in Quality of Life after thyroidectomy for benign thyroid disease with secondary characteristics of the patients ( eg age, thyroid autoimmunity, thyroid function, Vitamin D levels) Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your

2018 Clinical Trials

89. Psychological Status and Related Factors of Thyroid Related Eye Disease

Sponsor: Huijing Ye Information provided by (Responsible Party): Huijing Ye, Sun Yat-sen University Study Details Study Description Go to Brief Summary: The purpose of this study is to evaluate the psychological status of Thyroid Related Eye Disease. Condition or disease Intervention/treatment Thyroid Related Eye Disease Behavioral: psychological condition Detailed Description: The purpose of this study is to evaluate the psychological status of patients of Thyroid Related Eye Disease over 16 years (...) ) Outcome Measures Go to Primary Outcome Measures : Quality of life questionnaire of patients of Thyroid Related Eye Disease [ Time Frame: immediately ] Graves ́ ophthalmopathy quality of life questionnaire (GO-QoL) , The GO-QoL contains 8 questions on visual functioning and 8 questions on appearance; answers on each subscale are transformed to scores ranging from 0 (worst) to 100 (best). Secondary Outcome Measures : Symptom checklist 90(SLC-90) [ Time Frame: immediately ] It consists of 90 items

2018 Clinical Trials

90. Radiofrequency Ablation of Low Risk Papillary Thyroid Microcarcinoma

: February 14, 2018 See Sponsor: Seoul National University Hospital Information provided by (Responsible Party): Ji-hoon Kim, Seoul National University Hospital Study Details Study Description Go to Brief Summary: This is a single center prospective clinical trial with regard to efficacy and safety of radiofrequency ablation of papillary thyroid microcarcinoma. Condition or disease Intervention/treatment Phase Papillary Thyroid Microcarcinoma Thyroid Cancer Procedure: RFA for PTMC Not Applicable Detailed (...) and hydrodissection, if indicated, will be used. After RFA, follow-up will be performed using ultrasonography, serum thyroid function test, and questionnaire for quality of life by face-to-face interview at 2 months, 6, 12, 18, 24 months during the first 2 years after RFA, and yearly afterwards. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 100 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary

2018 Clinical Trials

91. Effect of Reversed Tracking Method for Identification of EBSLN in Thyroid Surgery

Update Posted : November 9, 2018 See Sponsor: Fujian Medical University Information provided by (Responsible Party): Bo Wang,MD, Fujian Medical University Study Details Study Description Go to Brief Summary: The feasibility and effectiveness of Reversed Tracking Method for the identification and protection of extralaryngeal nerve branches in thyroid surgery were analyzed. Evidence-based medical evidence was used to evaluate the importance of EBSLN recognition and protection in thyroid surgery (...) Effect of Reversed Tracking Method for Identification of EBSLN in Thyroid Surgery Effect of Reversed Tracking Method for Identification of EBSLN in Thyroid Surgery - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding

2018 Clinical Trials

92. Reference intervals of thyroid hormones in Khartoum, Sudan (PubMed)

Reference intervals of thyroid hormones in Khartoum, Sudan This study aimed to establish the reference intervals (RIs) of thyroid function test among the adult Sudanese population in Khartoum, Sudan. A multi-stage survey stratified sampling method was used. Total triiodothyronine (TT3), total thyroxine (TT4) level and thyroid stimulating hormone (TSH) levels were measured using radioimmunoassay gamma counter (Riostad, Germany) to determine the reference intervals.A total of 390 adults aged 20 (...) increase with age. In summary the RIs for TSH, TT4 and TT3 in this setting were different from the levels provided by the manufacturers. A significant different was observed in TSH and FT4 when considering gender issue. The RIs were not different in the different age groups except for FT4.

Full Text available with Trip Pro

2018 BMC research notes

93. LncRNA SNHG15 acts as a ceRNA to regulate YAP1-Hippo signaling pathway by sponging miR-200a-3p in papillary thyroid carcinoma (PubMed)

miR-200a-3p. Moreover, results of gain-of-function assays validated the anti-oncogenic function of miR-200a-3p in papillary thyroid carcinoma. Finally, results of rescue assays validated the function of SNHG15-miR-200a-3p-YAP1 axis in papillary thyroid carcinoma. YAP1 is known as an oncogene and a core factor of Hippo pathway. Here, we demonstrated that SNHG15 inactivated Hippo signaling pathway in papillary thyroid carcinoma. In summary, our findings demonstrated that SNHG15 serves (...) expression of SNHG15 in human papillary thyroid carcinoma tissues and cell lines. Moreover, Kaplan-Meier method was utilized to analyze the internal relevance between SNHG15 expression and overall survival rate of patients with papillary thyroid carcinoma. Loss-of-function assays were designed and conducted to determine the inhibitory effects of silenced SNHG15 on the cell growth and migration in papillary thyroid carcinoma. The mechanical investigation indicated that SNHG15 upregulated YAP1 by sponging

Full Text available with Trip Pro

2018 Cell death & disease

94. LncRNA HCP5 promotes follicular thyroid carcinoma progression via miRNAs sponge (PubMed)

LncRNA HCP5 promotes follicular thyroid carcinoma progression via miRNAs sponge Long non-coding RNAs (lncRNAs), which are important functional regulators in cancer, have received increased attention in recent years. In this study, next-generation sequencing technology was used to identify aberrantly expressed lncRNAs in follicular thyroid carcinoma (FTC). The long non-coding RNA-HLA complex P5 (HCP5) was found to be overexpressed in FTC. The results of the qPCR analysis were consistent (...) that the expression of HCP5 was elevated and was correlated with the levels of ST6GAL2 in FTC tissues and cells. Mechanistic experiments showed that HCP5 functions as a competing endogenous RNA (ceRNA) and acts as a sponge for miR-22-3p, miR-186-5p and miR-216a-5p, which activates ST6GAL2. In summary, our study revealed that HCP5 is a tumour regulator in the development of FTC and that it may contribute to improvement of FTC diagnosis and therapy.

Full Text available with Trip Pro

2018 Cell death & disease

95. Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas

Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results (...) information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas (LENVOS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators

2018 Clinical Trials

96. The Correlation Between Iodine and Selenium Status in Pregnancy and Risk of Thyroid Disease

Posted : December 3, 2018 Last Update Posted : December 3, 2018 See Sponsor: Rongrong Li Information provided by (Responsible Party): Rongrong Li, Peking Union Medical College Hospital Study Details Study Description Go to Brief Summary: Two hundred and ninety pregnant women with gestational age less than 20 weeks will be recruited in this study. Selenium and iodine conditions, and risk of thyroid disease will be monitored until termination of pregnancy, with pregnancy outcomes recorded. Condition (...) concentrations, serum selenium concentrations, etc). The nutritional status of iodine and selenium will be monitored and followed up for all the included subjects throughout the pregnancy. The information of thyroid function and level of anti-TPO and anti-TG will be collected. And all the complications (especially thyroid disease) in pregnancy will also be recorded. All pregnant women will be followed up until the termination of pregnancy, with pregnancy outcomes recorded. Study Design Go to Layout table

2018 Clinical Trials

97. Effectiveness of Intraoperative Neuromonitoring of External Branch of Superior Laryngeal Nerve During Thyroid Surgery

. ClinicalTrials.gov Identifier: NCT03773120 Recruitment Status : Recruiting First Posted : December 12, 2018 Last Update Posted : December 13, 2018 See Sponsor: Seoul National University Hospital Information provided by (Responsible Party): Su-jin Kim, Seoul National University Hospital Study Details Study Description Go to Brief Summary: The paralysis of the external branch of superior laryngeal nerves after thyroid surgery is known to be a common complication resulting in poor quality of life. Aim (...) . However, there is controversy regarding usefulness in preserving EBSLN function using nerve monitoring system. The aim of the study is to evaluate effectiveness of neuromonitoring during thyroid surgery for the preservation of EBSLNs. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 126 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Outcomes Assessor) Primary Purpose

2018 Clinical Trials

98. Thyroid Cancer Treatment (PDQ®): Patient Version

Thyroid Cancer Treatment (PDQ®): Patient Version Thyroid Cancer Treatment (Adult) (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf Warning: The NCBI web site requires JavaScript to function. Search database Search term Search NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): ; 2002 (...) -. Search term Thyroid Cancer Treatment (Adult) (PDQ®) Patient Version PDQ Adult Treatment Editorial Board . Published online: May 23, 2018. This PDQ cancer information summary has current information about the treatment of adult thyroid cancer. It is meant to inform and help patients, families, and caregivers. It does not give formal guidelines or recommendations for making decisions about health care. Editorial Boards write the PDQ cancer information summaries and keep them up to date. These Boards

2016 PDQ - NCI's Comprehensive Cancer Database

99. Diagnostic use of thyrotropin alfa-rch for Patients with Well-Differentiated Thyroid Cancer

Diagnostic use of thyrotropin alfa-rch for Patients with Well-Differentiated Thyroid Cancer 1 Public Summary Document Application 1156: The diagnostic use of thyrogen for patients with well-differentiated thyroid cancer Applicant: Genzyme Australasia Date of MSAC consideration: 29 March 2012. 1. Purpose of application In December 2010, the Department of Health and Ageing received an application from Genzyme Australasia, the Australian distributor of the Thyrogen® brand of thyrotropin alfa-rch (...) assessments for recurrence of thyroid cancer constitute the primary source of evidence. The submission of evidence from the Applicant does not provide a summary of the comparative safety outcomes from the studies presented in the submission of evidence. The submission of evidence states that an “independent government evaluation concluded that Thyrogen® was safe and efficacious for therapeutic use”. The submission of evidence states that: “Thyrogen® is typically well-tolerated with short-lived (<48 hours

2012 Medical Services Advisory Committee

100. Association of non-alcoholic fatty liver disease (NAFLD) with thyroid function: a systematic review and meta-analysis

Association of non-alcoholic fatty liver disease (NAFLD) with thyroid function: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence (...) , language, journal. ">Data to be extracted: other as well as a to meta-analysis of pre-clinical studies are available. Example: A meta‐analysis will be performed for all outcome measures reported in 10 or more articles. For subgroup analysis a minimum of 8 studies per subgroup is required. If meta‐analysis is not possible, data will be reported through a descriptive summary. ">Planned approach Example: number of metastases: standardized mean difference; incidence of metastasis: risk ratio. ">Effect

2018 PROSPERO

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>